Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients

Experimental Hematology

Volumn 41, Issue 12, 2013, Pages 1008-1015

  Michallet, Mauricette ^a,i   Sobh, Mohamad ^a   El Cheikh, Jean ^b   Morisset, Stéphane ^a   Sirvent, Anne ^c   Reman, Oumedaly ^d   Cornillon, Jérôme ^e   Tabrizi, Reza ^f   Milpied, Noel ^f   Harousseau, Jean Luc ^g   Labussière, Hélène ^a   Nicolini, Franck Emmanuel ^a   Attal, Michel ^h   Moreau, Philippe ^g   Mohty, Mohamad ^g   Blaise, Didier ^b   Avet Loiseau, Hérvé ^h  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^d CAEN UNIVERSITY HOSPITAL   (France)

^e Hematology   (France)

^f BORDEAUX UNIVERSITY HOSPITAL   (France)

^g HÔTEL DIEU   (France)

^h TOULOUSE UNIVERSITY HOSPITAL   (France)

ⁱ Pavillon Marcel Berard bâtiment 1G ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; BUSULFAN; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; ENGRAFTMENT; FEMALE; HIGH RISK PATIENT; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; TREATMENT OUTCOME;

ADULT; AGED; BORONIC ACIDS; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROSPECTIVE STUDIES; PYRAZINES; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84888864923     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2013.08.003     Document Type: Article

References (43)

1. Anderson K.C. The role of immunomodulatory drugs in multiple myeloma. Semin Hematol 2003, 40(4 Suppl 4):23-32.
2. Kumar S.K., Rajkumar S.V., Dispenzieri A., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111:2516-2520.
3. Palumbo A., Anderson K. Multiple myeloma. N Engl J Med 2011, 364:1046-1060.
4. Blade J., Rosinol L., Cibeira M.T., Rovira M., Carreras E. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 2010, 115:3655-3663.
5. Bensinger W.I., Buckner C.D., Anasetti C., et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996, 88:2787-2793.
6. Lokhorst H., Einsele H., Vesole D., et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol 2010, 28:4521-4530.
7. Garban F., Attal M., Michallet M., et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006, 107:3474-3480.
8. Rotta M., Storer B.E., Sahebi F., et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood 2009, 113:3383-3391.
9. Giaccone L., Storer B., Patriarca F., et al. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood 2011, 117:6721-6727.
10. Bjorkstrand B., Iacobelli S., Hegenbart U., et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol 2011, 29:3016-3022.
11. Richardson P.G., Weller E., Lonial S., et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010, 116:679-686.
12. Kneppers E., van der Holt B., Kersten M.J., et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood 2011, 118:2413-2419.
13. Wolschke C., Stubig T., Hegenbart U., et al. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study. Exp Hematol 2013, 41:134-142.e133.
14. Beitinjaneh A.M., Saliba R., Bashir Q., et al. Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant. Leuk Lymphoma 2012, 53:1525-1529.
15. Blade J., Samson D., Reece D., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998, 102:1115-1123.
16. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974, 18:295-304.
17. Kaplan E.L., Meier P. Non parametric estimationfrominomplete observations. J Am Stat Assoc 1958, 53:457.
18. Cox D.R. Regression models and life tables. J Royal Stat Soc B 1972, 34:187-220.
19. Nath C.E., Shaw P.J. Busulphan in blood and marrow transplantation: dose, route, frequency and role of therapeutic drug monitoring. Curr Clin Pharmacol 2007, 2:75-91.
20. Mohty M., Boiron J.M., Damaj G., et al. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004, 34:77-84.
21. Bird J.M., Owen R.G., D'Sa S., et al. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 2011, 154:32-75.
22. Fermand J.P., Katsahian S., Divine M., et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005, 23:9227-9233.
23. Barlogie B., Kyle R.A., Anderson K.C., et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006, 24:929-936.
24. Attal M., Lauwers-Cances V., Marit G., et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012, 366:1782-1791.
25. McCarthy P.L., Owzar K., Hofmeister C.C., et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012, 366:1770-1781.
26. Kumar S.K., Lacy M.Q., Dispenzieri A., et al. Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer 2012, 118:1585-1592.
27. Cavo M., Di Raimondo F., Zamagni E., et al. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. J Clin Oncol 2009, 27:5001-5007.
28. Benson D.M., Panzner K., Hamadani M., et al. Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma. Leuk Lymphoma 2010, 51:243-251.
29. El-Cheikh J., Michallet M., Nagler A., et al. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. Haematologica 2008, 93:455-458.
30. Koreth J., Stevenson K.E., Kim H.T., et al. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood 2009, 114:3956-3959.
31. Gahrton G., Iacobelli S., Bjorkstrand B., et al. Autologous/reduced-intensity allogeneic stem cell transplantation versus autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood 2013, 121:5055-5063.
32. Bruno B., Rotta M., Patriarca F., et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007, 356:1110-1120.
33. Rosinol L., Perez-Simon J.A., Sureda A., et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008, 112:3591-3593.
34. Moreau P., Garban F., Attal M., et al. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood 2008, 112:3914-3915.
35. Lokhorst H. No RIC in high-risk myeloma?. Blood 2006, 107:3420-3421.
36. Krishnan A., Pasquini M.C., Logan B., et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011, 12:1195-1203.
37. Avet-Loiseau H., Attal M., Campion L., et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol 2012, 30:1949-1952.
38. Lokhorst H.M., van der Holt B., Cornelissen J.J., et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood 2012 Jun 28, 119:6219-6225.
39. Lokhorst H.M., Wu K., Verdonck L.F., et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004, 103:4362-4364.
40. Salama M., Nevill T., Marcellus D., et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000, 26:1179-1184.
41. Peggs K.S., Thomson K., Hart D.P., et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 2004, 103:1548-1556.
42. van de Donk N.W., Kroger N., Hegenbart U., et al. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006, 37:1135-1141.
43. Peggs K.S., Mackinnon S., Williams C.D., et al. Reduced-intensity transplantation with invivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant 2003, 9:257-265.